symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
OCGN,0.426,3.702963,2924921,109264311,0,0.39-1.87,-0.007,"Ocugen, Inc.",USD,0001372299,US67577C1053,67577C105,NASDAQ Capital Market,NASDAQ,Biotechnology,https://www.ocugen.com,"Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.","Dr. Shankar  Musunuri M.B.A., MBA, Ph.D.",Healthcare,US,84,484 328 4701,263 Great Valley Parkway,Malvern,PA,19355,0.776932,2.04693,https://financialmodelingprep.com/image-stock/OCGN.png,2014-12-03,False,False,True,False,False
